Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Hembruff, Stacey L ^a   Laberge, Monique L ^b   Villeneuve, David J ^a   Guo, Baoqing ^a   Veitch, Zachary ^b   Cecchetto, Melanie ^a   Parissenti, Amadeo M ^a,b,c  

^a SUDBURY REGIONAL HOSPITAL   (Canada)

^b LAURENTIAN UNIVERSITY   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN A; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCC4 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CYCLOSPORIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; RIBONUCLEOPROTEIN; TAXOID; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SELECTION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSPORT KINETICS; ANALYSIS OF VARIANCE; DNA MICROARRAY; DRUG RESISTANCE; METABOLISM; NONPARAMETRIC TEST; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CYCLOSPORINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P-GLYCOPROTEIN; PACLITAXEL; STATISTICS, NONPARAMETRIC; TAXOIDS; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 57649188662     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-318     Document Type: Article

References (52)

1. Kudoh K Ramanna M Ravatn R Elkahloun AG Bittner ML Meltzer PS Trent JM Dalton WS Chin KV Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray Cancer Res 2000, 60:4161-4166. 10945624
2. Longley DB Johnston PG Molecular mechanisms of drug resistance J Pathol 2005, 205:275-292. 10.1002/path.1706 15641020
3. Gottesman MM Fojo T Bates SE Multidrug resistance in cancer: Role of ATP-dependent transporters Nat Rev Cancer 2002, 2:48-58. 10.1038/nrc706 11902585
4. Kruh GD Introduction to resistance to anticancer agents Oncogene 2003, 22:7262-7264. 10.1038/sj.onc.1206932 14576836
5. Sparreboom A Danesi R Ando Y Chan J Figg WD Pharmacogenomics of ABC transporters and its role in cancer chemotherapy Drug Resist Updat 2003, 6:71-84. 10.1016/S1368-7646(03)00005-0 12729805
6. Szakacs G Varadi A Ozvegy-Laczka C Sarkadi B The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox) Drug Discov Today 2008, 13:379-393. 10.1016/ j.drudis.2007.12.010 18468555
7. Zaman GJ Flens MJ van Leusden MR de HM Mulder HS Lankelma J Pinedo HM Scheper RJ Baas F Broxterman HJ The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump Proc Natl Acad Sci USA 1994, 91:8822-8826. 44698 7916458 10.1073/ pnas.91.19.8822
8. Cole SP Sparks KE Fraser K Loe DW Grant CE Wilson GM Deeley RG Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells Cancer Res 1994, 54:5902-5910. 7954421
9. Choi CH ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal Cancer Cell Int 2005. 5:30. 1277830 16202168 10.1186/1475-2867-5-30
10. Hoffmann U Kroemer HK The ABC transporters MDR1 and MRP2: Multiple functions in disposition of xenobiotics and drug resistance Drug Metab Rev 2004, 36:669-701. 10.1081/DMR-200033473 15554242
11. Taniguchi K Wada M Kohno K Nakamura T Kawabe T Kawakami M Kagotani K Okumura K Akiyama S Kuwano M A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation Cancer Res 1996, 56:4124-4129. 8797578
12. Tian Q Zhang J Tan TM Chan E Duan W Chan SY Boelsterli UA Ho PC Yang H Bian JS Human multidrug resistance associated protein 4 confers resistance to camptothecins Pharm Res 2005, 22:1837-1853. 10.1007/ s11095-005-7595-z 16132345
13. Leggas M Adachi M Scheffer GL Sun D Wielinga P Du G Mercer KE Zhuang Y Panetta JC Johnston B Mrp4 confers resistance to topotecan and protects the brain from chemotherapy Mol Cell Biol 2004, 24:7612-7621. 506999 15314169 10.1128/MCB.24.17.7612-7621.2004
14. Chen ZS Lee K Walther S Raftogianis RB Kuwano M Zeng H Kruh GD Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system Cancer Res 2002, 62:3144-3150. 12036927 12036927
15. Greenberger LM Lothstein L Williams SS Horwitz SB Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines Proc Natl Acad Sci USA 1988, 85:3762-3766. 280298 2897689 10.1073/pnas.85.11.3762
16. Liu ZL Onda K Tanaka S Toma T Hirano T Oka K Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA Cancer Chemother Pharmacol 2002, 49:391-397. 10.1007/s00280-001-0411-5 11976833
17. Dean M Rzhetsky A Allikmets R The human ATP-binding cassette (ABC) transporter superfamily Genome Res 2001, 11:1156-1166. 10.1101/ gr.GR-1649R 11435397
18. Chen G Jaffrezou JP Fleming WH Duran GE Sikic BI Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection Cancer Res 1994, 54:4980-4987. 7915196
19. Ross DD Yang W Abruzzo LV Dalton WS Schneider E Lage H Dietel M Greenberger L Cole SP Doyle LA Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines J Natl Cancer Inst 1999, 91:429-433. 10.1093/jnci/91.5.429 10070941
20. Allen JD Schinkel AH Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2) Mol Cancer Ther 2002, 1:427-434. 12477055
21. Doyle LA Ross DD Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 2003, 22:7340-7358. 10.1038/ sj.onc.1206938 14576842
22. Robey RW Medina-Perez WY Nishiyama K Lahusen T Miyake K Litman T Senderowicz AM Ross DD Bates SE Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells Clin Cancer Res 2001, 7:145-152. 11205902
23. Robey RW Honjo Y Morisaki K Nadjem TA Runge S Risbood M Poruchynsky MS Bates SE Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity Br J Cancer 2003, 89:1971-1978. 10.1038/ sj.bjc.6601370 14612912
24. Honjo Y Hrycyna CA Yan QW Medina-Perez WY Robey RW van de LA Litman T Dean M Bates SE Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells Cancer Res 2001, 61:6635-6639. 11559526
25. Mossink MH van ZA Scheper RJ Sonneveld P Wiemer EA Vaults: A ribonucleoprotein particle involved in drug resistance? Oncogene 2003, 22:7458-7467. 10.1038/sj.onc.1206947 14576851
26. Abbondanza C Rossi V Roscigno A Gallo L Belsito A Piluso G Medici N Nigro V Molinari AM Moncharmont B Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cell J Cell Biol 1998, 141:1301-1310. 2132791 9628887 10.1083/jcb.141.6.1301
27. Chugani DC Rome LH Kedersha NL Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex J Cell Sci 1993, 106(Pt 1):23-29. 8270627
28. Cheng SH Lam W Lee AS Fung KP Wu RS Fong WF Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution Toxicol Appl Pharmacol 2000, 164:134-142. 10.1006/taap.2000.8903 10764626
29. Seymour L Bezwoda WR Dansey RD P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer Breast Cancer Res Treat 1995, 36:61-69. 10.1007/BF00690186 7579508
30. Linn SC Pinedo HM van Ark-Otte J van d V Hoekman K Honkoop AH Vermorken JB Giaccone G Expression of drug resistance proteins in breast cancer, in relation to chemotherapy Int J Cancer 1997, 71:787-795. 10.1002/ (SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.0.CO;2-5 9180147
31. Carter A Dann EJ Katz T Shechter Y Oliven A Regev R Eytan E Rowe JM Eytan GD Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1 Br J Haematol 2001, 114:581-590. 10.1046/j.1365-2141.2001.02969.x 11552983
32. Chintamani MS Singh JP Mittal MK Saxena S Bansal A Bhatia A Kulshreshtha P Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study World J Surg Oncol 2005, 3:61. 1224882 16164742 10.1186/1477-7819-3-61
33. Holt van der B Lowenberg B Burnett AK Knauf WU Shepherd J Piccaluga PP Ossenkoppele GJ Verhoef GE Ferrant A Crump M The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis Blood 2005, 106:2646-2654. 10.1182/blood-2005-04-1395 15994288
34. Pusztai L Wagner P Ibrahim N Rivera E Theriault R Booser D Symmans FW Wong F Blumenschein G Fleming DR Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma Cancer 2005, 104:682-691. 10.1002/cncr.21227 15986399
35. Guo B Villeneuve DJ Hembruff SL Kirwan AF Blais DE Bonin M Parissenti AM Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure Breast Cancer Res Treat 2004, 85:31-51. 10.1023/ B:BREA.0000021046.29834.12 15039596
36. Guo B Hembruff SL Villeneuve DJ Kirwan AF Parissenti AM Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization Breast Cancer Res Treat 2003, 82:125-141. 10.1023/B:BREA.0000003969.21267.81 14692656
37. Villeneuve DJ Hembruff SL Veitch Z Cecchetto M Dew WA Parissenti AM cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance Breast Cancer Res Treat 2006, 96:17-39. 10.1007/ s10549-005-9026-6 16322897
38. Hembruff SL Villeneuve DJ Parissenti AM The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data Anal Biochem 2005, 345:237-249. 10.1016/j.ab.2005.07.014 16139235
39. Seidman AD Hochhauser D Gollub M Edelman B Yao TJ Hudis CA Francis P Fennelly D Gilewski TA Moynahan ME Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer J Clin Oncol 1996, 14:1877-1884. 8656256
40. Mross K Hollander N Frost A Unger C Ziroli V Massing U PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing Onkologie 2006, 29:444-450. 10.1159/000095243 17028453
41. Tjuljandin SA Doig RG Sobol MM Watson DM Sheridan WP Morstyn G Mihaly G Green MD Pharmacokinetics and toxicity of two schedules of high dose epirubicin Cancer Res 1990, 50:5095-5101. 2379173
42. Swenson CE Bolcsak LE Batist G Guthrie TH Jr Tkaczuk KH Boxenbaum H Welles L Chow SC Bhamra R Chaikin P Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer Anticancer Drugs 2003, 14:239-246. 10.1097/ 00001813-200303000-00008 12634619
43. Ejendal KF Hrycyna CA Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A Mol Pharmacol 2005, 67:902-911. 10.1124/mol.104.001701 15598974
44. Qadir M O'Loughlin KL Fricke SM Williamson NA Greco WR Minderman H Baer MR Cyclosporin A is a broad-spectrum multidrug resistance modulator Clin Cancer Res 2005, 11:2320-2326. 10.1158/1078-0432.CCR-04-1725 15788683
45. Mark PJ Waddell BJ P-glycoprotein restricts access of cortisol and dexamethasone to the glucocorticoid receptor in placental BeWo cells Endocrinology 2006, 147:5147-5152. 10.1210/en.2006-0633 16873536
46. Hu YP Chapey C Robert J Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation Cancer Lett 1996, 109:203-209. 10.1016/S0304-3835(96)04454-0 9020922
47. Egashira M Kawamata N Sugimoto K Kaneko T Oshimi K P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833 Blood 1999, 93:599-606. 9885221
48. Kaszubiak A Holm PS Lage H Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes Int J Oncol 2007, 31:419-430. 17611700
49. Chen XP Wang Q Guan J Huang ZY Zhang WG Zhang BX Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells World J Gastroenterol 2006, 12:3332-3337. 16733848
50. Takeda M Mizokami A Mamiya K Li YQ Zhang J Keller ET Namiki M The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines Prostate 2007, 67:955-967. 10.1002/pros.20581 17440963
51. Kaiserova H Kvasnickova E Inhibition study of rabbit liver cytosolic reductases involved in daunorubicin toxication J Enzyme Inhib Med Chem 2005, 20:477-483. 10.1080/14756360500141994 16335056
52. Hung JJ Chow KC Wang HW Wang LS Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung Anticancer Res 2006, 26:2949-2955. 16886619